Geode Capital Management
CRDL

Geode Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Geode Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.8K Hold
52,435
– – ﹤0.01% 4229
2025
Q4 		$50K Hold
52,435
– – ﹤0.01% 4233
2025
Q3 		$56.1K Hold
52,435
– – ﹤0.01% 4267
2025
Q2 		$71.3K Hold
52,435
– – ﹤0.01% 4152
2025
Q1 		$50.9K Hold
52,435
– – ﹤0.01% 4196
2024
Q4 		$67.1K Hold
52,435
– – ﹤0.01% 4189
2024
Q3 		$104K Hold
52,435
– – ﹤0.01% 4092
2024
Q2 		$106K Hold
52,435
– – ﹤0.01% 4123
2024
Q1 		$94.9K Hold
52,435
– – ﹤0.01% 4173
2023
Q4 		$44K Hold
52,435
– – ﹤0.01% 4382
2023
Q3 		$48.2K Hold
52,435
– – ﹤0.01% 4427
2023
Q2 		$46.7K Hold
52,435
– – ﹤0.01% 4518
2023
Q1 		$25.6K Hold
52,435
– – ﹤0.01% 4659
2022
Q4 		$26K Hold
52,435
– – ﹤0.01% 4726
2022
Q3 		$54K Hold
52,435
– – ﹤0.01% 4750
2022
Q2 		$69K Hold
52,435
– – ﹤0.01% 4697
2022
Q1 		$80K Hold
52,435
– – ﹤0.01% 4713
2021
Q4 		$97K Hold
52,435
– – ﹤0.01% 4744
2021
Q3 		$217K Buy
+52,435
New +$190K ﹤0.01% 4415

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management's CRDL Position: Q1 2026 in Review

Geode Capital Management held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 52,435 shares worth $70.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4229.

Geode Capital Management first reported a position in CRDL in Q3 2021 and has held it in 19 quarters since. The position peaked at $217K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Geode Capital Management held 52,435 shares of Cardiol Therapeutics worth $70.8K as of Q1 2026.
  • Geode Capital Management left its Cardiol Therapeutics share count unchanged in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4229 holding.
  • Geode Capital Management first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Cardiol Therapeutics position peaked at $217K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.